Karlberg L - Search Results

1

Long-term physical activity and lower urinary tract symptoms in men.

Orsini N, RashidKhani B, Andersson SO, Karlberg L, Johansson JE, Wolk A. Orsini N, et al. Among authors: karlberg l. J Urol. 2006 Dec;176(6 Pt 1):2546-50; discussion 2550. doi: 10.1016/j.juro.2006.07.030. J Urol. 2006. PMID: 17085155

2

Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men.

Andersson SO, Rashidkhani B, Karlberg L, Wolk A, Johansson JE. Andersson SO, et al. Among authors: karlberg l. BJU Int. 2004 Aug;94(3):327-31. doi: 10.1111/j.1464-410X.2004.04930.x. BJU Int. 2004. PMID: 15291861

3

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4. Bill-Axelson A, et al. J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. doi: 10.1093/jnci/djn255. Epub 2008 Aug 11. J Natl Cancer Inst. 2008. PMID: 18695132 Free PMC article. Clinical Trial.

4

Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.

Stattin P, Bergh A, Karlberg L, Tavelin B, Damber JE. Stattin P, et al. Among authors: karlberg l. Eur Urol. 1997;32(4):404-9. Eur Urol. 1997. PMID: 9412796 Clinical Trial.

5

Percent Gleason grade 4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Egevad L, et al. Among authors: karlberg l. J Urol. 2002 Aug;168(2):509-13. J Urol. 2002. PMID: 12131299

6

Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer.

Stattin P, Damber JE, Karlberg L, Bergh A. Stattin P, et al. Among authors: karlberg l. J Urol. 1997 Jan;157(1):219-22. J Urol. 1997. PMID: 8976256

7

Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment.

Josefsson A, Wikström P, Granfors T, Egevad L, Karlberg L, Stattin P, Bergh A. Josefsson A, et al. Among authors: karlberg l. Eur Urol. 2005 Oct;48(4):577-83. doi: 10.1016/j.eururo.2005.05.016. Eur Urol. 2005. PMID: 15990221

8

Prognostic value of the Gleason score in prostate cancer.

Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Egevad L, et al. Among authors: karlberg l. BJU Int. 2002 Apr;89(6):538-42. doi: 10.1046/j.1464-410x.2002.02669.x. BJU Int. 2002. PMID: 11942960

9

Long-term outcome of patients treated for hydrocele with the sclerosant agent sodium tetradecyl sulphate.

Stattin P, Karlberg L, Damber JE. Stattin P, et al. Among authors: karlberg l. Scand J Urol Nephrol. 1996 Apr;30(2):109-13. doi: 10.3109/00365599609180899. Scand J Urol Nephrol. 1996. PMID: 8738055

10

p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer.

Stattin P, Bergh A, Karlberg L, Nordgren H, Damber JE. Stattin P, et al. Among authors: karlberg l. Eur Urol. 1996;30(1):65-72. doi: 10.1159/000474147. Eur Urol. 1996. PMID: 8854070

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters